Alice H. Berger, Ph.D. - Publications

Affiliations: 
2011 Weill Cornell Medical College, New York, NY, United States 
Area:
Cell Biology, Genetics, Molecular Biology, Oncology

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Moorthi S, Berger AH. All about that Ras: Novel fusion drives Ras pathway activation in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35512219 DOI: 10.1158/1078-0432.CCR-22-0736  0.354
2022 Caicedo JC, Arevalo J, Piccioni F, Bray MA, Hartland CL, Wu X, Brooks AN, Berger AH, Boehm JS, Carpenter AE, Singh S. Cell Painting predicts impact of lung cancer variants. Molecular Biology of the Cell. mbcE21110538. PMID 35353015 DOI: 10.1091/mbc.E21-11-0538  0.33
2022 Ursu O, Neal JT, Shea E, Thakore PI, Jerby-Arnon L, Nguyen L, Dionne D, Diaz C, Bauman J, Mosaad MM, Fagre C, Lo A, McSharry M, Giacomelli AO, Ly SH, ... ... Berger AH, et al. Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nature Biotechnology. PMID 35058622 DOI: 10.1038/s41587-021-01160-7  0.326
2021 Riley AK, Berger AH. Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer. Molecular & Cellular Oncology. 8: 2000318. PMID 35419481 DOI: 10.1080/23723556.2021.2000318  0.326
2021 Parrish PCR, Thomas JD, Gabel AM, Kamlapurkar S, Bradley RK, Berger AH. Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome. Cell Reports. 36: 109597. PMID 34469736 DOI: 10.1016/j.celrep.2021.109597  0.32
2021 Vichas A, Riley AK, Nkinsi NT, Kamlapurkar S, Parrish PCR, Lo A, Duke F, Chen J, Fung I, Watson J, Rees M, Gabel AM, Thomas JD, Bradley RK, Lee JK, ... ... Berger AH, et al. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nature Communications. 12: 4789. PMID 34373451 DOI: 10.1038/s41467-021-24841-y  0.432
2021 Mathsyaraja H, Catchpole J, Freie B, Eastwood E, Babaeva E, Geuenich M, Cheng PF, Ayers J, Yu M, Wu N, Moorthi S, Poudel KR, Koehne A, Grady W, Houghton AM, ... Berger AH, et al. Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness. Elife. 10. PMID 34236315 DOI: 10.7554/eLife.64212  0.375
2021 Thornton AM, Fang L, Lo A, McSharry M, Haan D, O'Brien C, Berger AH, Giannakis M, Brooks AN. eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants. Plos Computational Biology. 17: e1009132. PMID 34214079 DOI: 10.1371/journal.pcbi.1009132  0.367
2021 Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, ... ... Berger A, ... ... Berger AH, et al. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Reports. 34: 108707. PMID 33535033 DOI: 10.1016/j.celrep.2021.108707  0.344
2020 Thomas JD, Polaski JT, Feng Q, De Neef EJ, Hoppe ER, McSharry MV, Pangallo J, Gabel AM, Belleville AE, Watson J, Nkinsi NT, Berger AH, Bradley RK. RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons. Nature Genetics. PMID 31911676 DOI: 10.1038/S41588-019-0555-Z  0.321
2020 Moorthi S, Paguirigan A, Anderson G, Porter P, Holden M, Ha G, Berger A. A24 The Genome-Wide Mutational Landscape of Lung Cancer in Never-Smokers: The Women’s Health Initiative (WHI) Cohort Journal of Thoracic Oncology. 15: S20. DOI: 10.1016/j.jtho.2019.12.053  0.349
2019 Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Lascio SD, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, et al. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-01  0.37
2019 Vichas A, Nkinsi NT, Berger A. Abstract 2726: Functional multiomic profiling identifies Aurora kinase inhibition as a therapeutic strategy inRIT1-mutant lung adenocarcinoma Cancer Research. 79: 2726-2726. DOI: 10.1158/1538-7445.Sabcs18-2726  0.551
2019 Lo A, McSharry M, Berger A. Abstract 4345: A large-scale RNA-seq screen to identify regulators of alternative splicing in cancer Cancer Research. 79: 4345-4345. DOI: 10.1158/1538-7445.Am2019-4345  0.469
2018 Chen M, Zhang J, Berger AH, Diolombi MS, Ng C, Fung J, Bronson RT, Castillo-Martin M, Thin TH, Cordon-Cardo C, Plevin R, Pandolfi PP. Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. The Journal of Clinical Investigation. PMID 30475228 DOI: 10.1172/Jci99699  0.56
2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Berger AH, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035  0.427
2018 Holmes KD, Mundt F, Mertins P, Carr S, Berger A. Abstract B24: Differential sensitivity to Aurora kinase inhibition in RIT1- and KRAS-mutant lung adenocarcinoma Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Aacriaslc18-B24  0.519
2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, Dimitriadoy S, Liu DL, Kantheti HS, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, ... ... Berger AH, et al. Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas Cancer Research. 78: 3302-3302. DOI: 10.1158/1538-7445.Am2018-3302  0.443
2017 Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Watson J, et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 32: 884. PMID 29232558 DOI: 10.1016/j.ccell.2017.11.008  0.437
2017 Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma. Cancer Research. PMID 28522754 DOI: 10.1158/0008-5472.Can-16-1944  0.525
2017 Peled N, Lu X, Greer J, Wu W, Choi P, Berger A, Hann B, Meyerson M, Collisson E. P2.03b-042 MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma Journal of Thoracic Oncology. 12: S961. DOI: 10.1016/J.Jtho.2016.11.1323  0.454
2016 Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. Jci Insight. 1: e87062. PMID 27882345 DOI: 10.1172/Jci.Insight.87062  0.395
2016 Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Watson J, et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. PMID 27478040 DOI: 10.1016/J.Ccell.2016.06.022  0.532
2016 Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics. PMID 27158780 DOI: 10.1038/Ng.3564  0.439
2016 Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Kaplan N, et al. Abstract 4368: High-throughput phenotyping of lung cancer somatic mutations Cancer Research. 76: 4368-4368. DOI: 10.1158/1538-7445.Am2016-4368  0.56
2015 Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, et al. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery. 5: 550-63. PMID 25653093 DOI: 10.1158/2159-8290.Cd-13-1050  0.449
2015 Albiges L, Murray B, Brooks A, Cherniack A, Berger A, Creighton CJ, Ricketts C, Bottaro DP, Srinivasan R, Schmidt LS, Meyerson M, Spellman P, Linehan WM, Choueiri TK. Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. Journal of Clinical Oncology. 33: 4521-4521. DOI: 10.1200/Jco.2015.33.15_Suppl.4521  0.425
2015 Berger A, Brooks A, Wu X, Hogstrom L, Tirosh I, Piccioni F, Bagul M, Zhu C, Shretha Y, Root D, Tamayo P, Sakai R, Wong B, Subramanian A, Golub T, et al. Abstract PR12: High-throughput gene expression profiling as a generalizable assay for determination of mutation impact on gene function Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr12  0.523
2015 Berger AH, Kim E, Brooks A, Ilic N, Shrestha Y, Tseng Y, Wu X, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Kantoff P, et al. Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants Cancer Research. 75: 957-957. DOI: 10.1158/1538-7445.Transcagen-Pr07  0.49
2015 Berger A, Brooks A, Wu X, Hogstrom L, Tirosh I, Piccioni F, Bagul M, Zhu C, Shretha Y, Root D, Tamayo P, Sakai R, Wong B, Subramanian A, Golub T, et al. Abstract PR04: High-throughput gene expression profiling as a generalizable assay for determination of mutation impact on gene function Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr04  0.521
2015 Berger A, Kim E, Brooks A, Shrestha Y, Tseng Y, Wu X, Ilic N, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Doench J, et al. Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2015-957  0.332
2014 Berger AH, Imielinski M, Duke F, Wala J, Kaplan N, Shi GX, Andres DA, Meyerson M. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 33: 4418-23. PMID 24469055 DOI: 10.1038/onc.2013.581  0.439
2014 Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger AH, Saglio G, Pandolfi PP. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. Leukemia. 28: 1326-33. PMID 24317448 DOI: 10.1038/Leu.2013.370  0.477
2014 Berger AH, Brooks AN, Imielinski M, Cherniack A, Duke F, Kaplan N, Wala J, Meyerson M. Abstract PR08:NF1,MET, andRIT1mutations are RAS-pathway driver events in lung adenocarcinoma Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr08  0.548
2014 Berger AH, Duke F, Imielinski M, Kaplan N, Wala J, Shi G, Andres DA, Meyerson M. Abstract PR02: Recurrent oncogenic mutations in the small GTPaseRIT1activate PI3K and MEK. Clinical Cancer Research. 20: PR02-PR02. DOI: 10.1158/1078-0432.14Aacriaslc-Pr02  0.469
2013 Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP. DOK2 inhibits EGFR-mutated lung adenocarcinoma. Plos One. 8: e79526. PMID 24255704 DOI: 10.1371/Journal.Pone.0079526  0.608
2013 Jung J, Pedamallu CS, Kostic AD, Freeman S, Ojesina AI, Berger A, Bhatt A, Duke F, Getz G, Meyerson M. Abstract 1501: Pan-cancer PathSeq analysis on TCGA data for pathogen discovery. Cancer Research. 73: 1501-1501. DOI: 10.1158/1538-7445.Am2013-1501  0.382
2013 Berger A, Imielinski M, Duke F, Wala J, Kaplan N, Shi G, Andres D, Meyerson M. Abstract C140: RIT1 mutations define a new genetic subset of lung adenocarcinoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C140  0.537
2012 Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150: 1107-20. PMID 22980975 DOI: 10.1016/J.Cell.2012.08.029  0.535
2012 Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proceedings of the National Academy of Sciences of the United States of America. 109: 14476-81. PMID 22908275 DOI: 10.1073/Pnas.1203201109  0.459
2012 Berger AH, Knudson AG, Pandolfi PP. Dosage and tumour suppression. The Journal of Pathology. 227: e1; author reply e2. PMID 22488586 DOI: 10.1002/Path.4035  0.496
2011 Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature. 476: 163-9. PMID 21833082 DOI: 10.1038/Nature10275  0.562
2011 Berger AH, Pandolfi PP. Haplo-insufficiency: a driving force in cancer. The Journal of Pathology. 223: 137-46. PMID 21125671 DOI: 10.1002/Path.2800  0.529
2010 Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP. Identification of DOK genes as lung tumor suppressors. Nature Genetics. 42: 216-23. PMID 20139980 DOI: 10.1038/Ng.527  0.592
Show low-probability matches.